Elan Tysabri Possible As 1st-Line Therapy

newratings.com - USA
0841 GMT [Dow Jones] Davy Stockbrokers says it's comfortable with peak MS sales forecasts for Elan's (ELN) Tysabri of $1.6B by 2010. ...
See all stories on this topic

EUROPEAN ADRS
MarketWatch - USA
... ADRs lost 4.1% to $15.84, adding to a 13% loss suffered the previous session, after US regulators restricted use of its multiple-sclerosis drug Tysabri. ...
See all stories on this topic

US authorities approve return of Elan's Tysabri drug
Unison.ie - Bray,Ireland
The Tysabri drug manufactured by the Irish-based multinational Elan is set to return to the market in the coming weeks after being given the all-clear by the ...

UK, Irish Stocks Decline on Interest Rate Concern; Elan Sinks
Bloomberg - USA
... Shares of the drugmaker dropped the most in a year after US regulators limited the sale of its Tysabri multiple-sclerosis medicine when it returns to the market ...
See all stories on this topic

Swiss shares close down sharply on Wall St led down by banks ...
Forbes - USA
... gainer in Zurich was Serono, up 10.5 sfr or 1.3 pct at 796.0 sfr, after the US Food and Drug Administration approved the reintroduction of Tysabri, a product ...
See all stories on this topic

Around the Nation
Arizona Daily Star - Tucson,AZ,USA
... won permission Monday to resume sales of their multiple sclerosis drug Tysabri, withdrawn last year after it was linked to a rare but potentially fatal brain ...

Next hurdle for Biogen's Tysabri MS drug: HMOs
Reuters - USA
CHICAGO/NEW YORK (Reuters) - US health officials may have allowed multiple sclerosis drug Tysabri back on the market, but drugmaker Biogen Idec Inc. ...
See all stories on this topic